Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Diagnostic and Prognostic Roles of Inflammatory Biomarkers in Coronary Heart Disease and Heart Failure Patients Treated With Empagliflozin.

NCT05911724 is registered in ClinicalTrials.gov with Damanhour University as lead sponsor.

NCT NCT05911724
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05911724 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Diagnostic and Prognostic Roles of Inflammatory Biomarkers in Coronary Heart Disease and Heart Failure Patients Treated With Empagliflozin.
Lead sponsor
Damanhour University
Phase
Observational
Overall status
Completed
Start date
March 1, 2023
Completion date
September 30, 2024
Enrollment
180 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

heart failure, stable angina